HomeCompareCLBTW vs ORCC

CLBTW vs ORCC: Dividend Comparison 2026

CLBTW yields 38.11% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBTW wins by $5.6K in total portfolio value
10 years
CLBTW
CLBTW
● Live price
38.11%
Share price
$5.25
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.0K
Annual income
$5.10
Full CLBTW calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — CLBTW vs ORCC

📍 CLBTW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBTWORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBTW + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLBTW pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBTW
Annual income on $10K today (after 15% tax)
$3,238.96/yr
After 10yr DRIP, annual income (after tax)
$4.34/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, CLBTW beats the other by $3.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBTW + ORCC for your $10,000?

CLBTW: 50%ORCC: 50%
100% ORCC50/50100% CLBTW
Portfolio after 10yr
$24.2K
Annual income
$3.07/yr
Blended yield
0.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

CLBTW
No analyst data
Altman Z
2.7
Piotroski
5/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBTW buys
0
ORCC buys
0
No recent congressional trades found for CLBTW or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBTWORCC
Forward yield38.11%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%-50%
Portfolio after 10y$27.0K$21.4K
Annual income after 10y$5.10$1.04
Total dividends collected$4.3K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: CLBTW vs ORCC ($10,000, DRIP)

YearCLBTW PortfolioCLBTW Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$12,605$1,905.27$11,190$489.61+$1.4KCLBTW
2$14,610$1,122.26$12,229$256.01+$2.4KCLBTW
3$16,240$607.82$13,216$130.74+$3.0KCLBTW
4$17,693$315.73$14,207$66.02+$3.5KCLBTW
5$19,092$160.73$15,234$33.17+$3.9KCLBTW
6$20,510$81.05$16,317$16.62+$4.2KCLBTW
7$21,986$40.68$17,468$8.32+$4.5KCLBTW
8$23,545$20.38$18,695$4.16+$4.8KCLBTW
9$25,204$10.20$20,006$2.08+$5.2KCLBTW
10$26,973$5.10$21,407$1.04+$5.6KCLBTW

CLBTW vs ORCC: Complete Analysis 2026

CLBTWStock

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. It provides Inseyets, a digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations. The company's digital forensics software also offers data extraction, decoding capabilities, workflows, and automation capabilities. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence by automating data analysis and visualization; Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data; and Guardian, a case and evidence management solution. Further, the company offers digital forensic software for enterprises and service providers, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now; and professional services, such as training and certification services, and other services. It serves federal and state and local agencies. The company was incorporated in 1999 and is headquartered in Petah Tikva, Israel.

Full CLBTW Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this CLBTW vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBTW vs SCHDCLBTW vs JEPICLBTW vs OCLBTW vs KOCLBTW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.